(Q36302860)

13 August 2017

1 reference

title

Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer (English)

1 reference

13 August 2017

1

Sofia Agelaki

1 reference

13 August 2017

Vassilis Georgoulias

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Emerging Drugs

13 August 2017

published in

1 reference

13 August 2017

volume

10

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

855-874

1 reference

Revisions in the International System for Staging Lung Cancer

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Epidermal growth factor receptors: critical mediators of multiple receptor pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

The biology of epidermal growth factor receptor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Tyrosine kinase inhibitors-ZD1839 (Iressa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Development of a serum-free medium for growth of NS-1 mouse myeloma cells and its application to the isolation of NS-1 hybridomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

The EGFR as a target for anticancer therapy--focus on cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

A new therapeutic antibody masks ErbB2 to its partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

HER1/EGFR targeting: refining the strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Cetuximab in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.4.855

10.1517/14728214.10.4.855

21 January 2018

Identifiers

DOI

1 reference

release_gqdarom2o5fajcqpfge5wbauji

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gqdarom2o5fajcqpfge5wbauji

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference